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 Introduction 
 Herpes simplex virus type 1 (HSV-1) is an important 
pathogen for humans and the discovery of novel effective 
antiherpetic drugs without adverse effects is of great in-
terest. The primary symptoms of herpes infection include 
a prodromal flu-like syndrome with fever, headache, mal-
aise, diffuse myalgias, followed by local symptoms con-
sisting of itching and painful papules. Gingivostomatitis 
and pharyngitis are the most frequent clinical manifesta-
tions of the first episodes of HSV-1 infection. After estab-
lishing latency, HSV can reactivate, causing frequent re-
current infections in some patients, while most people ex-
perience few recurrences  [1] . Recurrent herpes labialis is 
the most frequent clinical manifestation of reactivated 
HSV-1 infection. The clinical manifestation of the disease 
exhibits different severity in immunocompetent patients. 
However, in immunocompromised patients and neo-
nates, herpetic infections can cause serious systemic ill-
nesses  [2] . An antiviral treatment for HSV infection is 
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 Abstract 
 Background: Extracts and essential oils of medicinal plants 
are increasingly of interest as novel drugs for antiherpetic 
agents, since the herpes simplex virus (HSV) might develop 
resistance to commonly used antiviral drugs.  Methods: An 
aqueous extract of  Melissa officinalis as well as phenolic ex-
tract compounds, i.e. caffeic acid,  p -coumaric acid and ros-
marinic acid were examined for their antiviral activity against 
herpes simplex virus type 1 (HSV-1) in vitro.  Results: When 
drugs were added to HSV-1-infected cells, no antiviral effect 
was observed as determined by plaque reduction assay and 
analysis of expression of viral protein ICP0. However, the Me-
lissa extract demonstrated a high virucidal activity against 
HSV-1, even at very low concentrations of 1.5   g/ml, whereas 
similar results for phenolic compounds were only achieved 
at 100 times higher concentrations. Besides the virucidal ac-
tivity, the Melissa extract and rosmarinic acid inhibited HSV-
1 attachment to host cells in a dose-dependent manner. 
These results indicate that rosmarinic acid was the main con-
tributor to the antiviral activity of Melissa extract. However, 
the selectivity index of Melissa extract of 875 against HSV is 
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available since the introduction of acyclovir in the 1970s 
and is still the most commonly used chemotherapy  [3] . 
This nucleoside analogue functions as DNA chain termi-
nators, ultimately preventing elongation of viral DNA  [4] . 
The development of viral resistance towards  antiviral 
agents enhances the need for new effective  compounds 
against viral infections. Thus, new antiviral agents exhib-
iting different mechanisms of action are urgently needed.
 Medicinal plants produce a variety of chemical con-
stituents with the potential to inhibit viral replication, 
and compounds from natural sources are of interest as 
possible sources to control viral infection. These plants 
have been widely used in traditional medicine to treat a 
variety of infectious diseases and cancer  [5] and represent 
an abundant source of new bioactive secondary metabo-
lites.  Melissa officinalis (lemon balm) is a member of the 
Lamiaceae family and plants of this family are well known 
in antiviral phytotherapy  [6, 7] . Extracts from plants of 
the Lamiaceae family have been described for antioxi-
dant  [8] and antibacterial effects  [9, 10] which have been 
linked to their polyphenolic composition. An antiviral 
activity of lemon balm aqueous extracts has been de-
scribed previously  [11] , but no details on the mode of an-
tiviral action are available. Experimental as well as thera-
peutic effects of lemon balm extract  [12, 13] and rosemary 
 [14] against herpetic infections could be demonstrated in 
vitro and in vivo. Melissa leaves contain polyphenolic 
compounds, e.g. caffeic acid derivatives in large propor-
tions such as rosmarinic acid and also some flavonoids 
 [15] . Melissa has been evaluated for its activity against 
herpes viruses and HIV in some experimental models in 
vitro  [16, 17] . However, Melissa extract and its phenolic 
components caffeic acid,  p -coumaric acid and rosmarin-
ic acid have not been analyzed systematically for their 
antiviral potential. Thus only limited information about 
Melissa extract and phenolic compounds concerning the 
inhibition of the viral replication cycle and their mode of 
antiviral action is presently available.
 The goal of the present study is to evaluate the antivi-
ral activity of Melissa extract and selected phenolic com-
ponents against HSV-1 and their mode of antiviral ac-
tion.
 Materials and Methods 
 M. officinalis Extract and Phenolic Components 
 M. officinalis  extract was supplied by Lomapharm GmbH 
(Emmerthal, Germany) as dried powder. The drug-extract ratio 
was 70: 1, the dried extract corresponding to 1.43% of the primary 
raw Melissa leaf material. Usually 10 g raw material, correspond-
ing to 143 mg dried extract, is dissolved in 100 ml of the solvent. 
A stock solution was prepared by adding 100 ml of boiling water 
to 143 mg water-soluble Melissa powder followed by sterile filtra-
tion. HPLC analysis demonstrated phenolic compounds as con-
stituents, e.g. caffeic acid,  p -coumaric acid and rosmarinic acid. 
Besides essential oil, the major nonvolatile constituents in leaves 
of lemon balm are caffeic acid and its di- and trimeric derivatives, 
including rosmarinic acid and melitric acids A and B  [18–20] . In 
addition, flavonoids such as luteolin and its glycosides are also 
found in Melissa leaves  [21] . Serial dilutions were analyzed for 
cytotoxicity on monkey kidney cells and for antiviral effect 
against HSV. Caffeic acid,  p -coumaric acid and rosmarinic acid 
were purchased from Sigma-Aldrich (Taufkirchen, Germany) 
and Roth (Karlsruhe, Germany) and dissolved in ethanol. Acyclo-
vir was purchased from Mayne Pharma (Munich, Germany).
 Cell Culture and HSV-1 
 RC-37 cells (African green monkey kidney cells) were grown 
in a monolayer culture with Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco, Karlsruhe, Germany) supplemented with 5% fe-
tal calf serum (FCS; Gibco, Karlsruhe, Germany), 100 U/ml pen-
icillin and 100   g/ml streptomycin (Gibco, Karlsruhe, Germany). 
Cells were plated out into 96-well and 6-well culture plates for cy-
totoxicity and antiviral assays, respectively, and propagated at 
37   °   C in an atmosphere of 5% CO 2  [22] . HSV-1 strain KOS was 
used for all experiments. Viruses were routinely grown on RC-37 
cells and virus stock cultures were prepared from supernatants of 
infected cells and stored at –80   °   C. Infectivity titers were deter-
mined by a standard plaque assay on confluent RC-37 cells.
 Cytotoxicity Assay 
 The effect of Melissa extract and its components on the prolif-
eration of RC-37 cells was determined in 96-well tissue culture 
plates. A medium containing the appropriate dilution of the ex-
tract or compounds was added onto the subconfluent cells in eight 
replicates for each concentration of the drugs. Wells containing a 
medium with 1% ethanol but no compounds were also included 
on each plate as controls. After 3 days of incubation the growth 
medium was removed and the viability of the drug-treated cells 
was determined in a standard neutral red assay  [23] . The cyto-
toxic concentration of the drug which reduced the viable cell 
number by 50% (TC 50 ) was determined from dose-response 
curves. Additionally, the maximum noncytotoxic concentration 
of Melissa extract and each compound was determined  [16] .
 Plaque Reduction Assay 
 The assay was performed as described previously  [24] . Briefly, 
5  ! 10 5 cells per well were seeded into 6-well culture plates and 
then incubated until reaching at least 95% confluency. The cell 
monolayer was then infected with 100 pfu/well of drug-pretreated 
HSV-1. After incubation for 3 days at 37  °  C, monolayers were fixed 
with 10% formalin, stained with 1% crystal violet and subsequent-
ly plaques were counted. The minimal concentration of drugs re-
quired to reduce plaques by 50% (IC 50 ) was calculated by regres-
sion analysis of the dose-response curves  [24] . The selectivity in-
dex (SI) was determined as the ratio of TC 50 /IC 50. 
 Detection of ICP0 and gD Expression by Immunofluorescence 
 A total of 1.5  ! 10 5 RC-37 cells were seeded onto circular glass 
coverslips (12 mm, Assistent, Hecht, Sondheim, Germany) and 
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maintained in 24-well plates 1 day before infection. On the fol-
lowing day the cells were infected with HSV-1 (MOI = 1) for 1 h, 
washed, and cultured in a maintenance media with or without 
Melissa extract or its components. Cells were washed with PBS, 
fixed with 3% paraformaldehyde, permeabilized with 0.1% Triton 
X-100, and blocked with 1% bovine serum albumin (BSA) in PBS 
5 h and 7 h postinfection (p.i.) for detection of ICP0 and gD, re-
spectively. The coverslips were then incubated for 45 min at room 
temperature with mouse ICP0 or gD monoclonal antibodies (Vi-
rusys, Aachen, Germany). Afterwards, cells were washed and 
stained with 4,6-diamidino-2-phenylindole (DAPI; Sigma) and 
FITC-conjugated goat anti-mouse monoclonal antibodies for an-
other 45 min at room temperature. The coverslips were mounted 
and analyzed using immunoflorescence microscopy  [25] .
 Virucidal Assay and Attachment Assay 
 To determine the effect of Melissa extract and its components 
on direct inactivation of virus particles, HSV-1 (2  ! 10 5 pfu/100 
  l) was treated with an equal volume of drugs at room tempera-
ture. The concentration of Melissa extract was in the range of 
1.5–150   g/ml, caffeic acid 1–100   g/ml,  p -coumaric acid 10–
1,000   g/ml, and rosmarinic acid 1–100   g/ml. The highest con-
centration indicated was always the maximum noncytotoxic con-
centration of these drugs. After 1, 2, 4, or 6 h, 1,000-fold dilutions 
of the mixture were added to RC-37 cell monolayers for 1 h at 
37  °  C. The cell monolayers were overlaid with a media containing 
0.5% methylcellulose and 2% FBS to be plaque assayed  [26] .
 The attachment assay described by Cheng et al.  [26] was used 
in this study with a minor modification. Briefly, RC-37 cell mono-
layers were grown in 24-well culture plates and then prechilled at 
4   °   C for 1 h. The medium was aspirated and the cell monolayer 
was infected with 100 pfu/well of HSV in the absence or presence 
of serially diluted drugs up to the maximum noncytotoxic drug 
concentrations. After further incubating the infected cell mono-
layer at 4  °  C for another 3 h, the medium was aspirated to remove 
the unadsorbed virus. The cell monolayer was then washed with 
PBS 3 times, overlaid with a medium containing 0.5% methylcel-
lulose, and plaque assayed  [26] .
 Results 
 Analysis and Cytotoxicity of Melissa Extract and 
Phenolic Components 
 HPLC analysis demonstrated the presence of caffeic 
acid,  p -coumaric acid and rosmarinic acid in the Melissa 
extract, at a concentration of 1.6 , 0.1 , and 65.8 mg/g dried 
extract, respectively. Thus the composition of tested phe-
nolic compounds in the maximum noncytotoxic concen-
tration of Melissa extract (150   g/ml) is 0.16% (0.24   g/
ml) caffeic acid, 0.01% (0.015   g/ml)  p -coumaric acid, 
and 6.58% (9.75   g/ml) rosmarinic acid. Aqueous Me-
lissa extract and ethanolic solutions of caffeic acid,  p -cou-
maric acid and rosmarinic acid were serially diluted and 
added to a cell culture medium to examine the effect on 
the growth and viability of tissue culture cells, always re-
sulting in an ethanol concentration below 1% which had 
no effect on cells and viruses. The concentration ranges 
tested for Melissa extract, caffeic acid,  p -coumaric acid 
and rosmarinic acid were 1.43–715, 0.01–1,000, 0.01–
1,000 and 0.01–1,000   g/ml, respectively. The maximum 
noncytotoxic concentrations of these drugs were in the 
range of 100–1,000   g/ml, i.e. 100   g/ml for caffeic acid 
and rosmarinic acid and 1,000   g/ml for  p -coumaric 
acid, the drug which revealed the lowest cytotoxicity ( ta-
ble 1 ). The Melissa extract was still noncytotoxic up to a 
concentration of 150   g/ml. TC 50 values were 150   g/ml 
for caffeic acid, 350   g/ml for Melissa extract and  1 1,000 
  g/ml for  p -coumaric acid.
 Plaque Reduction Assay 
 Cell monolayers were infected with 100 pfu/well of 
drug-pretreated HSV-1. The concentration ranges tested 
for Melissa extract, caffeic acid,  p -coumaric acid and ros-
marinic acid were 1.43–150, 0.01–100, 0.01–1,000 and 
0.01–100   g/ml, respectively. The highest concentration 
of these drugs was always the maximum noncytotoxic 
concentration of Melissa extract, caffeic acid,  p -coumar-
ic acid and rosmarinic acid, i.e. 150, 100, 1,000 and 100 
  g/ml, respectively. After incubation for 3 days at 37  °  C, 
monolayers were fixed and plaques were counted. IC 50 
was calculated by regression analysis of the dose-response 
curves. IC 50 for Melissa extract, caffeic acid,  p -coumaric 
acid and rosmarinic acid was determined at 0.4, 35, 2.5 
and 10   g/ml, respectively. The SI was determined as a 
ratio of TC 50 /IC 50 . Melissa extract revealed the highest SI 
of 875 ( table 1 ).
 Expression of Herpes Virus Proteins ICP0 and gD 
 Expression of early viral protein ICP0 and late viral 
protein gD in HSV-1-infected cells was analyzed after 
Table 1.  SI of Melissa extract and single compounds against
HSV-1
Drug Max. noncyto-
toxic concen-
tration, g/ml 
TC50
g/ml 
IC50
g/ml
SI
Melissa extract 150810.0 350818.2 0.480.1 875
Caffeic acid 10085.1 15083.7 3586.3 4.3
p-Coumaric acid 1,00081.8 >1,000 2.583.6 >400
Rosmarinic acid 10080.1 200812.0 1082.1 20
Experiments were repeated independently and data presented were the 
mean 8 SD of three experiments.
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mock treatment or drug treatment. All drugs were ap-
plied at maximum noncytotoxic concentrations. Infected 
cells were fixed with 3% paraformaldehyde, permeabil-
ized with 0.1% Triton X-100 5 and 7 h p.i. for ICP0 or gD, 
respectively, incubated with mouse ICP0 and gD mono-
clonal antibodies and stained with DAPI and FITC-con-
jugated goat anti-mouse monoclonal antibodies. Immu-
nofluorescence revealed no effect of tested drugs on the 
expression of the herpes virus protein ICP0 and some in-
hibition of gD expression in drug-treated infected cells 
Acyclovir
Mock
DAPI ICP0
Caffeic acid
DAPI gD
Infected control
Melissa extract
p-Coumaric  acid
Rosmarinic acid
 Fig. 1. Effect of Melissa extract and pheno-
lic compounds on HSV-1 protein expres-
sion as determined by immunofluores-
cence microscopy. Infected cells were 
treated with maximum noncytotoxic con-
centration of plant extract, compounds 
and acyclovir 1 h p.i. Cells were fixed and 
stained at 5 and 7 h p.i. using antibodies 
against early protein ICP0 and late protein 
gD. Secondary antibodies were used to la-
bel viral proteins with FITC-conjugated 
goat anti-mouse monoclonal antibodies. 
Nuclei of cells were stained with DAPI. 
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( fig.  1 ). Thus some antiviral effect of the tested drugs 
could be demonstrated in infected cells during the late 
stage of HSV replication, but a higher potential antiviral 
effect might be exerted at earlier time points during the 
viral infection of cells.
 Virucidal and Attachment Assay 
 To determine the virucidal effect of Melissa extract 
and phenolic components against virus particles, HSV-1 
was treated at room temperature with serially diluted 
drugs, the highest concentration applied being the maxi-
mum noncytotoxic drug concentration. After 1, 2, 4, and 
6 h, these drug-treated viruses were highly diluted with a 
medium as typically performed in virucidal assays and 
added to the RC-37 cell monolayers. Melissa extract and 
phenolic compounds revealed a dose-dependent virucid-
al effect against HSV. After incubation of HSV for 1 h 
with maximum noncytotoxic concentrations of phenolic 
compounds, viral activity was reduced by 50–99% ( fig. 2 ). 
In contrast, Melissa extract revealed a  1 99% virus inac-
tivation at a concentration of 15   g/ml, a drug concentra-
tion tenfold below the maximum noncytotoxic concen-
tration. Thus the plant extract revealed the highest viru-
cidal activity against HSV-1.
 In virus attachment assays, again maximum noncyto-
toxic drug concentrations were applied, i.e. 150, 100, 
1,000 and 100   g/ml for Melissa extract, caffeic acid,  p -
coumaric acid and rosmarinic acid, respectively. Melissa 
extract and rosmarinic acid showed an inhibition of virus 
attachment to the host cells. For better comparison of the 
attachment inhibition of the tested drugs, all maximum 
noncytotoxic drug concentrations were 1: 2, 1: 10, 1: 20 and 
1: 100 diluted. Viral attachment was inhibited by 98% 
with Melissa extract at 7.5   g/ml, a drug concentration 
20 times below the maximum noncytotoxic concentra-
tion ( fig. 3 ). However, rosmarinic acid was less effective, 
even at a maximum noncytotoxic concentration of 100 
  g/ml, HSV-1 attachment was only reduced by about 
50%.
 Discussion 
 The results of studies on natural compounds are 
promising since several pure substances of plant origin 
have been shown to exhibit antiviral activity against HSV 
 [27, 28] . In the present study, the antiviral activity of 
 M. officinalis aqueous extract and three phenolic com-
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 Fig. 2. Virucidal activity of Melissa extract ( a ), caffeic acid ( b ),  p -coumaric acid ( c ) and rosmarinic acid ( d ). 
HSV-1 was incubated with drugs at indicated concentrations for 1, 2, 4, and 6 h at room temperature, followed 
by the dilution of the mixtures prior to their addition to cells. Mean  8 SD are representative of three indepen-
dent experiments. 
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pounds was analyzed for their antiviral activity against 
HSV in vitro. Experiments to assess the cytotoxicity of 
these drugs indicate a moderate toxic behavior in cell cul-
tures according to Halle and Göres  [29] . Expression of 
herpes virus early protein ICP0 was not affected by Me-
lissa extract, though some decrease in expression of the 
late HSV protein gD was detectable. However, staining of 
ICP0 was always superior to staining of gD even in un-
treated HSV-1-infected cells, thus a clear quantification 
of inhibition of gD expression is not possible. A hydroal-
coholic extract of  M. officinalis had been shown recently 
to be quite effective against intracellular HSV-2  [30] . 
However, in our study aqueous Melissa extract as well as 
phenolic compounds drastically affected the infectivity 
of HSV-1 only at the early stage of virus replication. Ros-
marinic acid is, at a concentration of 9.75   g/ml, the pre-
dominant phenolic compound in Melissa extract. It is the 
main contributor for the virucidal effect and significant-
ly inhibits herpes viral attachment. The IC 50 value of 10 
  g/ml for rosmarinic acid corresponds well to the actual 
concentration in the Melissa extract of 9.75   g/ml. The 
rather low concentrations of caffeic acid and  p -coumaric 
acid in the tested extract might not contribute to the an-
tiviral effect of the extract, since IC 50 values of these com-
pounds are quite higher. Similar results for caffeic acid 
which is also present in  Plantago major extracts have 
been reported previously, but the plant extract itself did 
not show antiherpetic activity  [31] . However, other yet 
unidentified compounds of Melissa extract might en-
hance the antiviral effect.
 Antiherpetic activity has been shown for aqueous 
plant extracts from  Echinacea pallidum  [32] ,  Rumex ace-
tosa  [33] and  Rhododendron ferrugineum  [34] , for poly-
saccharides derived from marine algae  [35] , for steroidal 
compounds against adenovirus  [36] and an ethylacetate-
soluble fraction from the lichen  Ramalina farinacea 
against HIV  [37] . Although all analyzed drugs in our 
study demonstrated virucidal activity, Melissa extract 
demonstrated a higher virucidal activity when compared 
to single compounds. Since all compounds tested in our 
study contribute to virucidicity against HSV, these com-
pounds might act together or synergistically in the plant 
extract. Complex interactions between phytochemicals 
and a multitarget therapeutic concept of phytotherapy 
have been demonstrated recently  [38] . Similar results 
have been shown for the antiherpetic effect of monoter-
penes and sesquiterpenes  [39] . The complex mixture of 
the Melissa extract revealed a higher antiviral activity 
and SI of 875, whereas analyzed single constituents dem-
onstrated lower SIs. Cos et al.  [40] recommended IC 50 
values for natural products against infectious diseases, 
e.g. for extracts below 100   g/ml. Melissa extract re-
vealed an IC 50 value of 0.4   g/ml in our study which is
far below the recommended cutoff.
 HSV-1 entry involves complex ligand-receptor inter-
actions and has been shown to be an ideal target for an-
tiviral compounds  [33, 41] . Melissa extract highly inhibits 
HSV attachment to host cells. In contrast, among the test-
ed phenolic compounds, only rosmarinic acid revealed 
some activity against attachment. Inhibition of adsorp-
tion and penetration of HSV by an aqueous extract from 
 Rhododendron ferrugineum has been reported previously 
 [34] . Similar results for inhibition of HSV attachment 
have been obtained with oligomeric proanthocyanidins 
from  Rumex acetosa  [33] . Garozzo et al.  [42] investigated 
the antiviral activity of the essential oil from  Melaleuca 
alternifolia  (tea tree oil), and found that all the main com-
ponents, i.e. terpinen-4-ol,   -terpinene,   -terpinene,  p -
cymene, terpinolene and   -terpineol, were ineffective 
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 Fig. 3. Effects of Melissa extract, caffeic acid,  p -coumaric acid and 
rosmarinic acid on virus attachment. Cell monolayers were pre-
chilled at 4   °   C for 1 h, then infected with HSV-1 serially diluted 
drugs and incubated for another 3 h. The percentage of inhibition 
of the test compound was evaluated by plaque assay. Inhibition of 
viral attachment was calculated in comparison to untreated con-
trols. Drug concentrations for Melissa extract, caffeic acid,  p -cou-
maric acid and rosmarinic acid at the maximum noncytotoxic 
concentrations (max. noncyt. conc.) are 150, 100, 1,000, 100   g/
ml, respectively; for the 1: 2 dilution, drug concentrations are 75, 
50, 500, 50   g/ml, respectively; for the 1: 10 dilution, drug concen-
trations are 15, 10, 100, 10   g/ml, respectively; for the 1: 20 dilu-
tion, drug concentrations are 7.5, 5, 50, 5   g/ml, respectively, and 
for the 1: 100 dilution, drug concentrations are 1.5, 1, 10, 1   g/ml, 
respectively. 
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against HSV-1 and HSV-2 and only a slight virucidal ef-
fect was observed for tea tree oil against these herpes vi-
ruses.
 In conclusion, the phenolic compound rosmarinic 
acid in the Melissa extract contributed mainly to the vi-
rucidal activity, but revealed a lower SI when compared 
to the complex plant extract. In contrast to single pheno-
lic compounds, Melissa extract additionally inhibited vi-
ral attachment and thus Melissa extract is preferable as
a topical prophylactic/therapeutic agent for HSV infec-
tions. Our results demonstrate an antiherpetic effect of 
 M. officinalis extract in vitro and support its traditional 
use in the topical treatment of recurrent herpes infection.
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